Doc Code:

PTO/SB/81 (01-06)

Approved for use through 12/31/2008. OMB 0651-0035

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number.

## POWER OF ATTORNEY CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/595,936			
Filing Date	May 19, 2006			
First Named Inventor	Mercep et al.			
Title	1,3-Diaza-Dibenzo[E,H]Azulenes For			
Art Unit				
Art Onit				
Examiner Name	1			

_				oy Bocker	1 2 2			
I here	by revoke all p	reviou	us powers of attorney given in the :	above-ider	itified application	on.	 	
I here	I hereby appoint:							
$\boxtimes$	Practitione	Practitioners associated with the Customer Number:				23347		
	OR			L			<u> </u>	
	Practitione	Practitioner(s) named below:						
	" 1	Name			Registration Number			
							1	
							1	
							1 	
							I	
as my United	r/our attorney(s d States Paten	s) or a it and	gent(s) to prosecute the applicatio Trademark Office connected there	n identified with.	d above, and to	transact a	l business in the	
Plea	ase recognize (	or cha	nge the correspondence address	for the abo	ve-identified a	oplication to	:	
	The address	assoc	iated with the above-mentioned Ci	ustomer N	umber:			
OR							1	
	The address	assoc	iated with Customer Number:				 	
OR							1	
LL	Firm or Individual Name	3					1	
Addres	38						1	
City				State	1	Z	ío I	
Countr	гу					1	r   	
Teleph	ione			Emal			1	
<u>I am t</u>	I am the:							
ļU .	Applicant/Invent	юг.					1	
	Assignee of record of the entire interest. See 37 CFR 3.71.  Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record								
Signature Robert A. Brunk Date 29						29 January 2017		
Name		Rober	rt H. Briok			Telephone	919-483/3323	
Title ar	nd Company	VP, G	laxoSmithKline				*"	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple								
<u> </u>	Total of		forms are submitted.					

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc Code: PLP532USW

PTO/SB/98 (09-06)

Approved for use through 03/31/2007. CMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pagerwork Reduction Act of 1985, no persona are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)							
Applicant/Patent Owner: GlaxoSmithKline Istrazivacki Centar	Zagreb D.O.O.						
Application No./Patent No.: 10/595,936	Filed/Issue Date: May 19, 2006						
Entitled: 1,3-Diaza-Dibenzo(E,H)Azulenes For The Treatment	Of Central Nervous System Diseases and Disorders						
BlaxoSmithKline Istrazivacki Centar Zagreb D.O.O. , a Corporation							
(Name of Assignee) (Type of Ass	gnee, e.g., corporation, partnership, university, government agency, etc.)						
states that it is:							
1.  the assignee of the entire right, title, and interest; or							
2. an assignee of less than the entire right, title and interest  The extent (by percentage) of its ownership interest is							
in the patent application/patent identified above by virtue of either:							
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at							
OR							
1. From:  To:  The document was recorded in the United States Patent and Traden Reel  Frame  To:  To:  To:  To:  To:  To:  The document was recorded in the United States Patent and Traden Reel  Frame  To:  To:  To:  To:  The document was recorded in the United States Patent and Traden Reel  To:  To:  The document was recorded in the United States Patent and Traden Reel  To:  To:  To:  To:  To:  To:  To:  The document was recorded in the United States Patent and Traden Reel  To:  To:  To:  To:  To:  To:  To:  The document was recorded in the United States Patent and Traden Reel  To:  To:  To:  To:  To:  To:  The document was recorded in the United States Patent and Traden Reel  To:  To:  To:  To:  To:  To:  The document was recorded in the United States Patent and Traden Reel  To:  To:  To:  To:  To:  To:  To:  To	copy thereof is attached.						
3. From: To:	'						
The document was recorded in the United States Patent and Trademark Office at  Reel , Frame , or for which a copy thereof is attached.							
Additional documents in the chain of title are listed on a suppleme	ntal sheet.						
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.  [NOTE: A separate copy (i.e., a true copy of the original assignment do accordance with 37 CFR Part 3, to record the assignment in the undersigned (whose title is supplied below) is authorized to act on behalf	ocument(s)) must be submitted to Assignment Division in the records of the USPTO. <u>See MPEP 302.08</u> ]						
Polent N. Back	29 January 2007						
Signature	/pate						
Robert H. Brink	919-483-3323						
Printed or Typed Name	Telephone number						
VP, GlaxoSmithkline	1						
Title	i						

This collection of information is required by 37 CFR 3,73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the upon the individual case. Any comments on the amount of the property of the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Power of Attorney

INO. 1873

two thousand and six BY THIS POWER OF ATTORNEY given this I'd day of WEY (2006), GlaxoSmithKline istraživački centar Zagreb d.o.o., a company incorporated in Croatia (Registry number of subject (MBS) 080471508) and having its registered office at Prilaz baruna Filipovica 29, Zagreb, HR-10000, Croatia (hereinafter called "the Company"), HEREBY appoints all and any of its Directors and Officers for the time being, and DAVID ROBERTS, PETER JOHN GIDDINGS, ARTHUR WILLIAM RUSSELL TYRRELL, HUGH BAINFORDE DAWSON, WENDY ANNE FILLER, MICHAEL JOHN STOTT, MARCUS JONATHAN WILLIAM DALTON, CHARLES KINZIG, STEPHEN VENETIANER, CHARLES E. DADSWELL and ROBERT H. BRINK jointly and severally to be its true and lawful agents and attorneys (hereinafter called "the Attorneys") on behalf and in the name of the Company or otherwise to do, perform, exercise or execute or concur with any other person or persons in doing, performing or exercising in or for any country or countries or jurisdiction in any part of the world all or any of the following powers, acts, deeds and things in connection with: letters patent, including extensions thereto; utility models; copyrights; trademark registrations; trademarks; trade names; trade dress; logos; design rights; designs and all rights analogous thereto and all applications therefor and any other forms whatsoever of intellectual property rights; including know-how, all of which are hereinafter called "Intellectual Property Rights", that is to say:

- 1. In any country or countries or jurisdiction in any part of the world to make application or cause application to be made for the grant or issue or transfer to the Company or registration in its name of intellectual Property Rights and to take all steps necessary for the same to be prosecuted, maintained, withdrawn, renewed, enforced, defended or extended.
- 2. As the act and deed of the Company to sign, seal, deliver and execute all or any assignments or assurances, licences to the Company of or under any intellectual Property Rights or the right to and interest in any inventions to be the subject of intellectual Property Rights for the purpose of fully and effectually vesting and transferring the same in and to the Company.
- As the act and deed of the Company to sign and execute all or any assignments and acceptances of the transfer or assignment of such rights, and also any licences, sublicences and consents from the Company of or under any Intellectual Property Rights or the right to and interest in any invention to be the subject of Intellectual Property Rights, for the purpose of fully and effectually vesting transferring or granting the same in and to any entity, whether in the United Kingdom or elsewhere, in so far as such documents can be executed without the Company's seal being affixed thereto. For purposes of this Power of Attorney, the terms "entity" means, and includes, any person, firm or company or group of persons or unincorporated body.
- To give undertakings or assurances to third parties and to any Trademark Registry or official intellectual property agency or governmental department or otherwise logos, design rights or designs for the purpose of best protecting or ensuring the coexistence of the Company's rights to trademarks, trade names, trade dress, logos, design rights or designs.
- 5. To commence, prosecute and defend any proceedings or applications whether judicial or extra judicial relating to Intellectual Property Rights and to maintain, withdraw or settle the same.
- 6. For and in connection with any Intellectual Property Rights to sign, seal, deliver and execute any Power of Attorney or other deed or document authorising any agent, including trademark and patent agents and attorneys, to act on behalf of the Company.

- To apply for the registration, amendment or cancellation of user rights in respect of any trademark or trade name.
- 8. To act in regard to all official communications which may now or hereafter be addressed to the Attorneys relating to Intellectual Property Rights or the renewal thereof in such manner that the Attorneys may be recognised as the authorised agent(s) of the Company in all proceedings in relation thereto.
- 9. For all or any of the purposes contained herein as the act and deed of the Company to sign, seal, deliver, execute and do all such documents, deeds, agreements, instruments and to do such acts as shall be requisite or may be deemed proper for or in relation to the said purposes.

AND THE COMPANY HEREBY RATIFIES and confirms and agrees to ratify and confirm all and whatsoever the Attorneys or any person, persons, firm or company appointed by them shall lawfully do or have done by virtue of the authorities herein contained

AND THE COMPANY HEREBY DECLARES that all instruments executed under and by virtue of this Power shall be as valid and effectual as if sealed by the Common Seal of the Company.

IN WITNESS whereof GiaxoSmithKline istraživački centar Zagreb d.o.o. has caused its Common Seal to be hereunto affixed the day and year first before written

This Power of Attorney of GlaxoSmithKline istraživački centar Zagreb d.o.o. was signed by:

Radan Spaventi

President of the Management Board

CiuxoSayithKiine Istraživački tentar Žegrob d.o.n. Zegrob, Priiz, imma Piirceviia 29 10